MX2020000353A - Metodos para incubar liquidos e inactivar virus. - Google Patents

Metodos para incubar liquidos e inactivar virus.

Info

Publication number
MX2020000353A
MX2020000353A MX2020000353A MX2020000353A MX2020000353A MX 2020000353 A MX2020000353 A MX 2020000353A MX 2020000353 A MX2020000353 A MX 2020000353A MX 2020000353 A MX2020000353 A MX 2020000353A MX 2020000353 A MX2020000353 A MX 2020000353A
Authority
MX
Mexico
Prior art keywords
incubating
liquids
inactivating viruses
inactivating
viruses
Prior art date
Application number
MX2020000353A
Other languages
English (en)
Inventor
Nikolaus Hammerschmidt
Jure Sencar
Alois Jungbauer
Duarte Lima Martins
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MX2020000353A publication Critical patent/MX2020000353A/es

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
    • B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
    • B01L3/502761—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip specially adapted for handling suspended solids or molecules independently from the bulk fluid flow, e.g. for trapping or sorting beads, for physically stretching molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F25/00—Flow mixers; Mixers for falling materials, e.g. solid particles
    • B01F25/40—Static mixers
    • B01F25/45—Mixers in which the materials to be mixed are pressed together through orifices or interstitial spaces, e.g. between beads
    • B01F25/452—Mixers in which the materials to be mixed are pressed together through orifices or interstitial spaces, e.g. between beads characterised by elements provided with orifices or interstitial spaces
    • B01F25/4524—Mixers in which the materials to be mixed are pressed together through orifices or interstitial spaces, e.g. between beads characterised by elements provided with orifices or interstitial spaces the components being pressed through foam-like inserts or through a bed of loose bodies, e.g. balls
    • B01F25/45241—Mixers in which the materials to be mixed are pressed together through orifices or interstitial spaces, e.g. between beads characterised by elements provided with orifices or interstitial spaces the components being pressed through foam-like inserts or through a bed of loose bodies, e.g. balls through a bed of balls
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F33/00—Other mixers; Mixing plants; Combinations of mixers
    • B01F33/30—Micromixers
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
    • B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
    • B01L3/502769—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip characterised by multiphase flow arrangements
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/06—Inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/00061—Methods of inactivation or attenuation
    • C12N2760/00063—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Clinical Laboratory Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Fluid Mechanics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)

Abstract

La presente invención se refiere a un método para incubar líquidos, a un método para preparar un fármaco biofarmacéutico y a un dispositivo para la preparación de un fármaco biofarmacéutico.
MX2020000353A 2017-07-10 2018-07-10 Metodos para incubar liquidos e inactivar virus. MX2020000353A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17180477 2017-07-10
EP18154196 2018-01-30
PCT/EP2018/068628 WO2019011900A1 (en) 2017-07-10 2018-07-10 METHOD FOR LIQUID INCUBATION AND VIRUS INACTIVATION

Publications (1)

Publication Number Publication Date
MX2020000353A true MX2020000353A (es) 2020-08-17

Family

ID=63209374

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020000353A MX2020000353A (es) 2017-07-10 2018-07-10 Metodos para incubar liquidos e inactivar virus.

Country Status (11)

Country Link
US (1) US20190022654A1 (es)
EP (1) EP3651811A1 (es)
JP (1) JP7218344B2 (es)
KR (1) KR102623471B1 (es)
CN (1) CN111050809B (es)
AU (1) AU2018299920B2 (es)
CA (1) CA3069593A1 (es)
CO (1) CO2020001426A2 (es)
MX (1) MX2020000353A (es)
SG (1) SG11202000269PA (es)
WO (1) WO2019011900A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3072885B1 (fr) * 2017-10-27 2019-11-15 IFP Energies Nouvelles Nouveau systeme de distribution par panneaux meridiens pour un procede de separation en lit mobile simule utilisant n-colonnes en serie
DE102018009597A1 (de) * 2018-12-07 2020-06-10 Sartorius Stedim Biotech Gmbh Vorrichtung und Verfahren zur mehrfachen Änderung der Zusammensetzung eines Fluids
US20230167417A1 (en) * 2020-04-30 2023-06-01 Massachusetts Institute Of Technology Model-based control for column-based continuous viral inactivation of biopharmaceuticals
US20220146485A1 (en) * 2020-11-12 2022-05-12 Essen Instruments, Inc. D/B/A Essen Bioscience, Inc. Viral clearance evaluation for biological medical product preparation processes

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214221B1 (en) * 1999-02-22 2001-04-10 Henry B. Kopf Method and apparatus for purification of biological substances
WO2001066216A1 (en) * 2000-03-09 2001-09-13 Transgenomic, Inc. Method and system for rna analysis by matched ion polynucleotide chromatography
IL136552A (en) * 2000-06-05 2005-05-17 Omrix Biopharmaceuticals Ltd Method for the inactivation of viruses by a solvent - detergent combination and by nanofiltration
CN1725998A (zh) * 2002-12-12 2006-01-25 旭化成株式会社 病毒除去袋及使用该病毒除去袋除去病毒的方法
AU2004253853B2 (en) * 2003-04-10 2010-04-01 Evonik Corporation A method for the production of emulsion-based micro particles
AU2005229674B2 (en) * 2004-11-18 2010-11-04 Kedrion Melville Inc. Low concentration solvent/detergent process of immuneglobulin with pre-treatment
KR102027596B1 (ko) * 2010-12-06 2019-10-01 타폰 바이오시스템즈, 인코포레이티드 생물학적 산물을 위한 연속 처리 방법
NZ611994A (en) * 2010-12-15 2015-04-24 Baxter Healthcare Sa Viral inactivation using improved solvent-detergent method
US9028678B2 (en) * 2011-06-28 2015-05-12 Phillips 66 Company Scrubbing hydrogen sulfide from hydrotreated product
EP2578286A1 (en) * 2011-10-04 2013-04-10 Merck Patent GmbH Method and apparatus for chromatographic purification
WO2013180648A1 (en) 2012-05-31 2013-12-05 Agency For Science, Technology And Research Methods for use of mixed multifunctional surfaces for reducing aggregate content in protein preparations
EP2682168A1 (en) * 2012-07-02 2014-01-08 Millipore Corporation Purification of biological molecules
EP3903599A1 (en) * 2013-09-25 2021-11-03 Bioverativ Therapeutics Inc. On-column viral inactivation methods
EP2918294A1 (de) * 2014-03-11 2015-09-16 Bayer Technology Services GmbH Vorrichtung und Verfahren zur kontinuierlichen Virusinaktivierung
EP4234569A3 (en) 2014-04-15 2023-10-18 Boehringer Ingelheim International GmbH Method and use for continuously inactivating a virus during manufacture of a biological product
EP3088006A1 (de) 2015-04-28 2016-11-02 Bayer Technology Services GmbH Verfahren zur kontinuierlichen virusinaktivierung in einem mikroreaktor
EP3141611A3 (en) * 2016-10-21 2017-05-10 Bayer Healthcare LLC Validation of continuous viral clearance

Also Published As

Publication number Publication date
CO2020001426A2 (es) 2020-02-28
KR102623471B1 (ko) 2024-01-09
US20190022654A1 (en) 2019-01-24
WO2019011900A1 (en) 2019-01-17
JP7218344B2 (ja) 2023-02-06
SG11202000269PA (en) 2020-02-27
CA3069593A1 (en) 2019-01-17
KR20200026955A (ko) 2020-03-11
AU2018299920B2 (en) 2024-04-11
RU2020105866A3 (es) 2022-02-25
EP3651811A1 (en) 2020-05-20
AU2018299920A1 (en) 2020-02-06
JP2020526210A (ja) 2020-08-31
CN111050809B (zh) 2021-12-24
RU2020105866A (ru) 2021-08-10
BR112020000524A2 (pt) 2020-07-21
CN111050809A (zh) 2020-04-21

Similar Documents

Publication Publication Date Title
ZA202107931B (en) Anti-tau antibodies and methods of use
MX2021006237A (es) Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos.
MX2019003735A (es) Formulaciones diluibles de cannabinoides y procesos para su preparacion.
EA201891339A1 (ru) Водный фармацевтический препарат, который содержит антитело к pd-l1 авелумаб
MX2020000353A (es) Metodos para incubar liquidos e inactivar virus.
PH12016501873A1 (en) Anti-influenza b virus hemagglutinin antibodies and methods of use
MX2020012132A (es) Compuestos de azapiridona y usos de los mismos.
PH12018501043A1 (en) Site specific her2 antibody drug conjugates
PH12016502061A1 (en) Novel antii-rnf43 antibodies and methods of use
MX2015016755A (es) Reagrupamiento del virus de influenza.
NZ761537A (en) Anti-human ox40l antibodies, uses & methods
WO2017171441A3 (ko) 페라이트계 촉매, 이의 제조방법 및 이를 이용한 부타디엔의 제조방법
MX2017003131A (es) Metodo para la preparacion de 2-alcoxi ciclohexanol.
MX2015011529A (es) Reordenamiento del virus de infuenza b.
EP3251698A4 (en) Ligand-cytotoxicity drug conjugate, preparing method therefor, and application thereof
MY197524A (en) System of multiple bags and method for the preparation of hemocomponents
MX2020007742A (es) Procesos para preparar fluorocetolidos.
MA42963A (fr) Préparation pharmaceutique anti-vieillissement
WO2016055647A3 (fr) Procede de preparation de plasma universel
EP3604268A4 (en) ALIPHATIC AMINE, ITS PREPARATION PROCESS AND ITS APPLICATIONS
MX2015009330A (es) Reordenamiento del virus de influenza.
EP3734476A4 (en) DATABASE SYSTEM AND METHOD AND DEVICE FOR REQUESTING A DATABASE
MX2016015298A (es) Inhibidores de nampt y metodos.
WO2015095659A3 (en) Indirubin solid dispersion composition
MX2016016398A (es) Preparacion de piperidin-4-carbotioamida.